On Friday, Shares of Allscripts Healthcare Solutions Inc (NASDAQ: MDRX), subtract -0.37% and shut at $10.85 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $10.84 and $11.37. Allscripts Healthcare Solutions (MDRX) declared recently that its Board of Directors has approved a new stock repurchase program under which Allscripts may purchase up to $200 million of its common stock through December 31, 2019.
The new stock repurchase program supersedes the formerly existing stock repurchase program, which authorized Allscripts to repurchase $150 million of its common stock through December 31, 2018. Under the prior program, Allscripts repurchased 8.1 million shares or about $97 million of shares of common stock.
Under the new program, Allscripts could repurchase about 18.4 million additional shares, or about 10 percent of the company’s outstanding shares as of October 30, 2016 based on the November 17, 2016 closing price.
Shares of Prudential Financial Inc (NYSE:PRU), added 0.70 % and shut at $99.15 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $98.51 and $99.66. The association’s commercial center capitalization is $42.63 Billion with the general uncommon loads of 431.70 million. The dramatic rise in life expectancy has improved human well-being but future longevity uncertainty also poses a real challenge to pension funding levels that plan sponsors will need to proactively manage, PGIM said recently in a new report. PGIM, among the world’s top 10 asset managers with more than $1 trillion in assets under administration, is the global investment administration businesses of Prudential Financial, Inc. (PRU).
The report, Longevity and Liabilities: Bridging the Gap, highlights that longevity risk has often taken a backseat to investment and interest rate risk. The underestimation of human life spans by forecasters and the potentially sharp unanticipated increases in longevity resulting from medical breakthroughs, such as anti-aging genetic treatments, poses a real risk to pension funding levels. This risk is compounded by the “lower for longer” interest rate environment that has burdened plan sponsors with low discount rates.